European medical journal. Diabetes最新文献

Chrono-nutrition and its Association with Chronotype and Blood Glucose Control Among People with Type 2 Diabetes 2型糖尿病患者时型营养及其与时型和血糖控制的关系

European medical journal. Diabetes Pub Date : 2023-10-25 DOI: 10.33590/emjdiabet/10300576

Suneeta S., Nupur S. Mehta, Neelam M. Rathod Neelam M. Rathod

{"title":"Chrono-nutrition and its Association with Chronotype and Blood Glucose Control Among People with Type 2 Diabetes","authors":"Suneeta S., Nupur S. Mehta, Neelam M. Rathod Neelam M. Rathod","doi":"10.33590/emjdiabet/10300576","DOIUrl":"https://doi.org/10.33590/emjdiabet/10300576","url":null,"abstract":"Background: Recent studies have revealed conflicting results for low glycaemic index (GI) meals in the prevention and treatment of metabolic disorders. Diurnal variations in glucose homeostasis, which are frequently overlooked in epidemiological studies, may help to explain some of these discrepancies. Food is an external cue to entrain the circadian rhythm, and meal timing is a crucial factor for glucose homeostasis. The study examines the relationship between chrono-nutrition, chronotype, and blood glucose control among people with Type 2 diabetes. Materials and Methods: Chrono-nutrition questionnaire assessed eating window, breakfast skipping, evening latency, evening eating, night eating, and largest meal of patients with Type 2 diabetes. Glycaemic control was assessed using a HbA1c test, fasting blood sugar, and 2-hour post-prandial blood sugar test. Insulin resistance was assessed by fasting triglyceride glucose index (TyG). Results: There was a significant association between late dining with dysglycaemia, irrespective of GI of the meal (p<0.05). Participants who had the largest meal during the active phase had better glycaemic control (p<0.05). Shorter eating windows and evening latency of at least 2 hours not only aided in glycaemic control, but also gave good sleep (p<0.05). Participants with the evening chronotype ate almost twice the amount of carbohydrates and fat at dinner than at breakfast. Evening chronotypes were associated with lesser servings of vegetables and fruits, and greater servings of sweets and caffeinated beverages, in comparison with morning chronotypes. Conclusions: Late diners had significantly worse blood glucose levels, irrespective of the GI of the meal. This may have public health implications, as calorie-dense meals are often consumed during late evenings, which can desynchronise the circadian rhythms. Eating meals as per the circadian rhythm could be an alternative non-pharmacological strategy to prevent diabetes and its complications.","PeriodicalId":91678,"journal":{"name":"European medical journal. Diabetes","volume":"11 4","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135216327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interview: Pia Leete 采访:Pia Leete

European medical journal. Diabetes Pub Date : 2023-10-24 DOI: 10.33590/emjdiabet/10309296

Pia Leete

引用次数: 0

Interview: Maggie Shepherd 采访:玛吉·谢泼德

European medical journal. Diabetes Pub Date : 2023-09-26 DOI: 10.33590/emjdiabet/10303060

Maggie Shepherd

引用次数: 0

Type 1 Diabetes and Health Information Systems: Lessons from Denmark 1型糖尿病和健康信息系统:丹麦的经验教训

European medical journal. Diabetes Pub Date : 2023-09-21 DOI: 10.33590/emjdiabet/10300830

David Beran, Kurt Højlund, Anders Green

{"title":"Type 1 Diabetes and Health Information Systems: Lessons from Denmark","authors":"David Beran, Kurt Højlund, Anders Green","doi":"10.33590/emjdiabet/10300830","DOIUrl":"https://doi.org/10.33590/emjdiabet/10300830","url":null,"abstract":"One of the components of a health system as defined by the World Health Organization (WHO) is data that the health system collects, generates, and uses to improve the health of its population. The aim of this paper is to describe key lessons from Denmark in planning, implementing, and using health system-generated data, using Type 1 diabetes as a tracer. A broad literature search was complemented with a review of grey literature, two series of interviews with Danish experts, and feedback from a presentation of these findings to two expert meetings. Denmark, through its unique identifier and data environment, enables the health system to collect a variety of data on Type 1 diabetes. Facilitators and challenges exist for data collection, data aggregation, use of data, communication of data and results, and intangible factors. For each of these, the environment, infrastructure, health system, and Danish society act as facilitators. Barriers relate to data being collected primarily for clinical and administrative purposes, and not necessarily for research, planning, policymaking, or advocacy. Fora are lacking to facilitate the communication and presentation of these results. An intangible element is the trust Danes have in their system, which is hard to replicate. As shown in the Danish setting, contextual factors cannot be negated in developing and implementing data-related solutions at a population level. The lessons from Denmark show that there is the need to conceive and act on all aspects of the data from its collection, aggregation, use, and communication. The last step of interaction between science and policy and practice requires a range of factors, including networks and knowledge brokers.","PeriodicalId":91678,"journal":{"name":"European medical journal. Diabetes","volume":"97 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136235462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Partial Clinical Remission of Type 1 Diabetes Mellitus in Children: Clinical Applications and Challenges with its Definitions. 儿童1型糖尿病的部分临床缓解:临床应用及其定义的挑战

European medical journal. Diabetes Pub Date : 2019-03-01 Epub Date: 2019-03-14

Benjamin Udoka Nwosu

{"title":"Partial Clinical Remission of Type 1 Diabetes Mellitus in Children: Clinical Applications and Challenges with its Definitions.","authors":"Benjamin Udoka Nwosu","doi":"","DOIUrl":"","url":null,"abstract":"The honeymoon phase, or partial clinical remission (PCR) phase, of Type 1 diabetes mellitus (T1DM) is a transitory period that is marked by endogenous insulin production by surviving 3 cells following a diabetes diagnosis and the introduction of insulin therapy. It is a critical window in the course of the disease that has short and long-term implications for the patient, such as a significant reduction in the risk of long-term complications of T1DM. To promote long-term cardiovascular health in children with newly diagnosed T1DM, three key steps are necessary: the generation of a predictive model for non-remission, the adoption of a user-friendly monitoring tool for remission and non-remission, and the establishment of the magnitude of the early-phase cardiovascular disease risk in these children in objective terms through changes in lipid profile. However, only about 50% of children diagnosed with T1DM experience the honeymoon phase. Accurate and prompt detection of the honeymoon phase has been hampered by the lack of an objective and easily applicable predictive model for its detection at the time of T1DM diagnosis, the complex formulas needed to confirm and monitor PCR, and the absence of a straightforward, user-friendly tool for monitoring PCR. This literature review discusses the most up-to-date information in this field by describing an objective predictive model for non-remission, an easy tool for monitoring remission or non-remission, and objective evidence for the cardiovascular protective effect of PCR in the early phase of the disease. The goal is to present non-remission as an independent clinical entity with significantly poorer long-term prognosis than partial remission.","PeriodicalId":91678,"journal":{"name":"European medical journal. Diabetes","volume":"4 1","pages":"89-98"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6502244/pdf/nihms-1022937.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37226134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ADDRESSING HYPERTENSION IN THE PATIENT WITH TYPE 2 DIABETES MELLITUS: PATHOGENESIS, GOALS, AND THERAPEUTIC APPROACH. 处理2型糖尿病患者的高血压:发病机制、目标和治疗方法。

European medical journal. Diabetes Pub Date : 2017-10-01

Ali A Rizvi

{"title":"ADDRESSING HYPERTENSION IN THE PATIENT WITH TYPE 2 DIABETES MELLITUS: PATHOGENESIS, GOALS, AND THERAPEUTIC APPROACH.","authors":"Ali A Rizvi","doi":"","DOIUrl":"","url":null,"abstract":"Hypertension is considered a powerful cardiovascular risk factor and is present in up to two-thirds of patients who suffer from diabetes. In the background of an established epidemiological association between lower blood pressure (BP) and improvement in long-term clinical outcomes, several large landmark trials and analyses have attempted to examine the possible benefit of tighter BP control in patients with Type 2 diabetes mellitus. Although aggressive BP targets in patients with diabetes have been advocated for a long time, currently accepted evidence from these studies has led to a general recommendation of systolic BP <140 mmHg and diastolic BP <90 mmHg. Therapy consists of lifestyle management, including weight loss if overweight or obese, a Dietary Approaches to Stop Hypertension (DASH)-style based nutrition counselling, and reduced sodium intake. Timely initiation and subsequent titration of antihypertensive medications to achieve individualised BP goals is recommended. A therapeutic agent that acts on the renin-angiotensin-aldosterone pathway, such as an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, should generally be included in the pharmacologic therapy for hypertension in patients with Type 2 diabetes mellitus. A multi-drug combination, particularly including a thiazide diuretic, is very often necessary and should be started early in the course of management. Finally, an accurate and standardised method of BP measurement in the outpatient setting is essential to ensure proper monitoring and gauge the effectiveness of treatment.","PeriodicalId":91678,"journal":{"name":"European medical journal. Diabetes","volume":"5 1","pages":"84-92"},"PeriodicalIF":0.0,"publicationDate":"2017-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679430/pdf/nihms916943.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35247367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TREATMENT OF TYPE 2 DIABETES WITH BIPHASIC INSULIN ANALOGUES. 双相胰岛素类似物治疗2型糖尿病。

European medical journal. Diabetes Pub Date : 2016-10-27 DOI: 10.33590/emjdiabet/10310988

A. Rizvi

引用次数: 7